Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis

被引：2
|
作者：
Medina-De la Garza, Carlos Eduardo [1 ,2 ]
Flores-Torres, Armando Salvador [1 ]
Garcia-Hernandez, Marisela [1 ,3 ,4 ]
de los Angeles Castro-Corona, Maria [1 ,2 ]
机构：
[1] Univ Autonoma Nuevo Leon, Immunomodulat Unit, Ctr Res & Dev Hlth Sci CIDICS, Monterrey, Mexico
[2] Univ Autonoma Nuevo Leon, Serv Immunol, Av Gonzalitos 235,Mitras Ctr, Monterrey 64460, Mexico
[3] Univ Autonoma Nuevo Leon, Biochem & Mol Med Dept, Sch Med, Monterrey, Mexico
[4] Univ Autonoma Nuevo Leon, Univ Hosp Dr Jose E Gonzalez, Av Gonzalitos 235,Mitras Ctr, Monterrey 64460, Mexico
来源：
MEDICAL HYPOTHESES | 2022年 / 160卷
关键词：
Diethylcarbamazine; Drug repurposing; Pulmonary fibrosis; COVID-19-related pulmonary fibrosis; Post-COVID-19;
D O I：
10.1016/j.mehy.2022.110774
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Antifibrotics for COVID-19 related lung fibrosis: agents with benefits?
    Mishra, Mayank
    Sindhwani, Girish
    ADVANCES IN RESPIRATORY MEDICINE, 2021, 89 (02) : 231 - 233
  • [22] Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
    George, Peter M.
    Wells, Athol U.
    Jenkins, R. Gisli
    LANCET RESPIRATORY MEDICINE, 2020, 8 (08): : 807 - 815
  • [23] The potential indicators for pulmonary fibrosis in survivors of severe COVID-19
    Huang, Wenhui
    Wu, Qingxia
    Chen, Zhuozhi
    Xiong, Zhiyuan
    Wang, Kun
    Tian, Jie
    Zhang, Shuixing
    JOURNAL OF INFECTION, 2021, 82 (02) : E5 - E7
  • [24] The prophylaxis and treatment potential of supplements for COVID-19
    Sahebnasagh, Adeleh
    Saghafi, Fatemeh
    Avan, Razieh
    Khoshi, Amirhosein
    Khataminia, Masoud
    Safdari, Mohammadreza
    Habtemariam, Solomon
    Ghaleno, Hassan Rezai
    Nabavi, Seyed Mohammad
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 887
  • [25] BPC 157 as Potential Treatment for COVID-19
    Deek, Sarah A.
    MEDICAL HYPOTHESES, 2022, 158
  • [26] Fluticasone propionate as a potential treatment for COVID-19
    McCarthy, Matthew W.
    DRUGS OF TODAY, 2022, 58 (05) : 241 - 247
  • [27] Promising and potential drugs for the treatment of COVID-19
    Moneriz, Carlos
    Castro-Salguedo, Cristian
    REVISTA CHILENA DE INFECTOLOGIA, 2020, 37 (03): : 205 - 215
  • [28] Linezolid a potential treatment for COVID-19 coinfections
    Moghadam, Vahid Damanpak
    Momenimovahed, Zohre
    Ghorbani, Maryam
    Khodadadi, Javad
    BRAZILIAN JOURNAL OF ANESTHESIOLOGY, 2021, 71 (02): : 198 - 198
  • [29] COVID-19: Melatonin as a potential adjuvant treatment
    Zhang, Rui
    Wang, Xuebin
    Ni, Leng
    Di, Xiao
    Ma, Baitao
    Niu, Shuai
    Liu, Changwei
    Reiter, Russel J.
    LIFE SCIENCES, 2020, 250
  • [30] A Radiation Mitigator as a Potential Treatment for COVID-19
    Corry, Peter M.
    Griffin, Robert J.
    RADIATION RESEARCH, 2020, 193 (06) : 505 - 505
12345